Stocks and Investing
Stocks and Investing
Thu, January 14, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Joseph Stringer Maintained (STOK) at Strong Buy with Increased Target to $65 on, Jan 14th, 2021
Joseph Stringer of Needham, Maintained "Stoke Therapeutics, Inc." (STOK) at Strong Buy with Increased Target from $56 to $65 on, Jan 14th, 2021.
Joseph has made no other calls on STOK in the last 4 months.
There are 3 other peers that have a rating on STOK. Out of the 3 peers that are also analyzing STOK, 0 agree with Joseph's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Joseph
- Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $72 on, Monday, December 28th, 2020
- Martin Auster of "Credit Suisse" Maintained at Buy with Increased Target to $49 on, Friday, November 13th, 2020
- Charles Duncan of "Cantor Fitzgerald" Initiated at Buy and Held Target at $49 on, Friday, October 23rd, 2020
Contributing Sources